Lactococcus lactis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization

被引：65

作者：

Audouy, Sandrine A. L.

van Roosmalen, Maarten L.

Neef, Jolanda

Kanninga, Rolf

Post, Eduard

van Deemter, Marielle

Metselaar, Heidi

van Selm, Saskia

Robillard, George T.

Leenhouts, Kees J.

Hermans, Peter W. M.

机构：

[1] BiOMaDe Technol, NL-9747 AG Groningen, Netherlands

[2] UMC St Radboud, Lab Pediat Infect Dis, NL-6525 EN Nijmegen, Netherlands

来源：

VACCINE | 2006年 / 24卷 / 26期

关键词：

mucosal vaccine; Lactococcus lactis; gram-positive enhancer matrix (GEM); Streptococcus pneumoniae; SlrA; PpmA; IgA1; protease;

D O I：

10.1016/j.vaccine.2006.03.054

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The present work reports the use of non-living non-recombinant bacteria as a delivery system for mucosal vaccination. Antigens are bound to the cell-wall of pretreated Lactococcus lactis, designated as Gram-positive enhancer matrix (GEM), by means of a peptidoglycan binding domain. The influence of the GEM particles on the antigen-specific serum antibody response was studied. Following nasal immunization with the GEM-based vaccines, antibody responses were induced at systemic and local levels. Furthermore, different GEM-based vaccines could be used consecutively in the same mice without adverse effects or loss of activity. Taken together, the results evidence the adjuvant properties of the GEM particles and indicate that GEM-based vaccines can be used repeatedly and are particularly suitable for nasal immunization purposes. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：5434 / 5441

页数：8

共 36 条

[31] Cell wall attachment of a widely distributed peptidoglycan binding domain is hindered by cell wall constituents [J].

Steen, A ;

Buist, G ;

Leenhouts, KJ ;

El Khattabi, M ;

Grijpstra, F ;

Zomer, AL ;

Venema, G ;

Kuipers, OP ;

Kok, J .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (26) :23874-23881

[32] EFFECTIVENESS OF CHOLERA TOXIN-B SUBUNIT AS AN ADJUVANT FOR NASAL INFLUENZA VACCINATION DESPITE PRE-EXISTING IMMUNITY TO CTB [J].

TAMURA, S ;

FUNATO, H ;

NAGAMINE, T ;

AIZAWA, C ;

KURATA, T .

VACCINE, 1989, 7 (06) :503-505

[33] Complete genome sequence of a virulent isolate of Streptococcus pneumoniae [J].

Tettelin, H ;

Nelson, KE ;

Paulsen, IT ;

Eisen, JA ;

Read, TD ;

Peterson, S ;

Heidelberg, J ;

DeBoy, RT ;

Haft, DH ;

Dodson, RJ ;

Durkin, AS ;

Gwinn, M ;

Kolonay, JF ;

Nelson, WC ;

Peterson, JD ;

Umayam, LA ;

White, O ;

Salzberg, SL ;

Lewis, MR ;

Radune, D ;

Holtzapple, E ;

Khouri, H ;

Wolf, AM ;

Utterback, TR ;

Hansen, CL ;

McDonald, LA ;

Feldblyum, TV ;

Angiuoli, S ;

Dickinson, T ;

Hickey, EK ;

Holt, IE ;

Loftus, BJ ;

Yang, F ;

Smith, HO ;

Venter, JC ;

Dougherty, BA ;

Morrison, DA ;

Hollingshead, SK ;

Fraser, CM .

SCIENCE, 2001, 293 (5529) :498-506

[34] Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria [J].

van Roosmalen, ML ;

Kanninga, R ;

El Khattabi, M ;

Neef, J ;

Audouy, S ;

Bosma, T ;

Kuipers, A ;

Post, E ;

Steen, A ;

Kok, J ;

Buist, G ;

Kuipers, OP ;

Robillard, G ;

Leenhouts, K .

METHODS, 2006, 38 (02) :144-149

[35] COMPARISON OF SYSTEMIC AND MUCOSAL PRIMING FOR MUCOSAL IMMUNE-RESPONSES TO A BACTERIAL PROTEIN ANTIGEN GIVEN WITH OR COUPLED TO CHOLERA-TOXIN (CT) B-SUBUNIT, AND EFFECTS OF PREEXISTING ANTI-CT IMMUNITY [J].

WU, HY ;

RUSSELL, MW .

VACCINE, 1994, 12 (03) :215-222

[36] Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env [J].

Xin, KQ ;

Hoshino, Y ;

Toda, Y ;

Igimi, S ;

Kojima, Y ;

Jounai, N ;

Ohba, K ;

Kushiro, A ;

Kiwaki, M ;

Hamajima, K ;

Klinman, D ;

Okuda, K .

BLOOD, 2003, 102 (01) :223-228

← 1 2 3 4 →